Duloxetine Lilly

RSS

duloxetine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Duloxetine Lilly. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Duloxetine Lilly.

For practical information about using Duloxetine Lilly, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 17/10/2019

Authorisation details

Product details
Name
Duloxetine Lilly
Agency product number
EMEA/H/C/004000
Active substance
duloxetine
International non-proprietary name (INN) or common name
duloxetine
Therapeutic area (MeSH)
  • Neuralgia
  • Diabetic Neuropathies
  • Depressive Disorder, Major
Anatomical therapeutic chemical (ATC) code
N06AX21
Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
08/12/2014
Contact address

Papendorpseweg 83
3528 BJ Utrecht
Netherlands

Product information

31/07/2019 Duloxetine Lilly - EMEA/H/C/004000 - R/0015

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psychoanaleptics

Therapeutic indication

Duloxetine Lilly is indicated in adults for:

  • Treatment of major depressive disorder
  • Treatment of diabetic peripheral neuropathic pain
  • Treatment of generalised anxiety disorder

Duloxetine Lilly is indicated in adults.

Assessment history

How useful was this page?

Add your rating
Average
1 rating